Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

The major target of the neutralizing antibody response to infection by the human immunodeficiency virus type 1 (HIV-1) is the outer envelope glycoprotein, gp120. The spectrum of HIV-1 neutralization specificity is currently represented by monoclonal antibodies (mAbs) that can be divided broadly into five groups. We have studied the binding of these mAbs to functional oligomeric and soluble monomeric gp120 derived from the molecular clone of a cell line-adapted isolate of HIV-1, and compared these binding properties with virus neutralization. Binding of all mAbs except those reactive with the V3 loop was much weaker to oligomeric than to monomeric gp120. This reduction in binding to oligomeric gp120 was determined mostly by a slower relative rate of association, although the dissociation rate also had some influence on relative variation in mAb affinity. Virus neutralization correlated broadly with mAb binding to the oligomeric rather than to the monomeric form of gp120, and neutralization potency was related to the estimated association rate. Thus, with the exception of the hypervariable V3 loop, regions of HIV-1 gp120 with the potential to induce a neutralization response are likely to be poorly presented for antibody recognition on the surface of cell line-adapted virions.

[1]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[2]  Amanda G. Fisher,et al.  A molecular clone of HTLV-III with biological activity , 1985, Nature.

[3]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[4]  G. Nakamura,et al.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. , 1986, Science.

[5]  G. Nakamura,et al.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.

[6]  N. Chang,et al.  Monoclonal Antibodies that Neutralize HIV–1 Virions and Inhibit Syncytium Formation by Infected Cells , 1987, Bio/Technology.

[7]  C. Boucher,et al.  Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. , 1988, AIDS.

[8]  G. Pauli,et al.  Fine structure of human immunodeficiency virus (HIV), immunolocalization of structural proteins and virus-cell relation , 1988 .

[9]  R. Weiss,et al.  Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.

[10]  A J Langlois,et al.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Goedert,et al.  Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. , 1988, Science.

[12]  H. Lyerly,et al.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. , 1988, AIDS research and human retroviruses.

[13]  J. Skehel,et al.  Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. , 1989, Virology.

[14]  T. Chang,et al.  A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. , 1989, Journal of immunology.

[15]  T. H. Lee,et al.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[16]  M. Emerman,et al.  Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding , 1989, Journal of virology.

[17]  K. Ikuta,et al.  Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens. , 1989, Virology.

[18]  R. Liskamp,et al.  Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. , 1989, The Journal of general virology.

[19]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[20]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[21]  L. Bacheler,et al.  HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. , 1990, AIDS research and human retroviruses.

[22]  L. Eckler,et al.  Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. , 1990, Journal of immunology.

[23]  P. Earl,et al.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Robinson,et al.  Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. , 1990, AIDS research and human retroviruses.

[25]  D. Dormont,et al.  Design and trials of AIDS vaccines. , 1990, Immunology today.

[26]  J. Levy,et al.  Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles , 1990, Journal of virology.

[27]  P. Earl,et al.  Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain , 1990, Journal of virology.

[28]  M. Hilgartner,et al.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. , 1991, Research in virology.

[29]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[30]  D. Ho,et al.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[32]  K. Steimer,et al.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.

[33]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[34]  T. Hideshima,et al.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. , 1991, Journal of immunology.

[35]  J. Laman,et al.  Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain , 1992, Journal of virology.

[36]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[37]  S. Zolla-Pazner,et al.  Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. , 1992, AIDS research and human retroviruses.

[38]  J. Moore,et al.  Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. , 1992, AIDS research and human retroviruses.

[39]  J. McKeating,et al.  Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20 , 1992 .

[40]  S. Zolla-Pazner,et al.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.

[41]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[42]  G K Lewis,et al.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.

[43]  J. Sodroski,et al.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.

[44]  N. Sullivan,et al.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.

[45]  Q. Sattentau,et al.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.

[46]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[47]  Q. Sattentau,et al.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.

[48]  J. Levy Pathogenesis of human immunodeficiency virus infection , 1989, Microbiological reviews.

[49]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.

[50]  S. Zolla-Pazner,et al.  Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. , 1994, Journal of immunology.

[51]  P. Charneau,et al.  Fusion from without directed by human immunodeficiency virus particles , 1994, Journal of virology.

[52]  P. Berman,et al.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.

[53]  M. Reitz,et al.  Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions , 1995, Journal of virology.

[54]  A. Trkola,et al.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B , 1995, Journal of virology.

[55]  C. Barbas,et al.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.

[56]  Q. Sattentau,et al.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.